SD Biosensor went public last year, indicating it planned to spend a portion of its earnings on acquisitions. #Meridian bioscience manual#This product manual is considered the intellectual property of Meridian Bioscience. This information is considered the intellectual property of Meridian Bioscience. The analysts said Meridian can benefit from the scale of SD Biosensor, whose revenue grew to $4 billion at the peak of the pandemic. Meridian Bioscience is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by. The principal executive office of the Company is 3471 River Hills Drive, Cincinnati, Ohio 45244. “In terms of performance, Meridian has been a standout in a disastrous year for the sector (and broader market) with the stock up 65% year-to-date and up 52% over the last 12 months,” they wrote, adding that the company has a clean balance sheet. Meridian Bioscience Inc is an integrated life science company. T his Schedule 13D (this Statement ) relates to the common stock, no par value (the Shares ), of Meridian Bioscience, Inc., a company incorporated in Ohio (the Company ). As COVID-19 Sales Retreat, Diagnostic Firms Turn Attention to Core. William Blair analysts wrote in a research note that the “valuation appears to be fair,” offering a 4.5-times multiple on the last 12 months of Meridian’s sales. Meridian Bioscience Preliminary Fiscal Q2 Revenues Rise by up to 33 Percent. distribution network and its “expertise in the regulated U.S. IVD market.” It plans to use SD Biosensor's research and development capabilities and “mass production know-how” alongside Meridian's U.S. Meridian Bioscience Participates in Piper Sandler 33rd Annual Virtual Healthcare Conference. Piper Sandler 33rd Annual Virtual Healthcare Conference. SDB Chairman Dr. Young Shik Cho said in the same statement that Meridian would be “a great partner for accelerating our entry into the U.S. Wainwright Bioconnect Virtual Conference. He added the sale will “drive further growth in the diagnostics space." “The transaction will enhance our ability to serve customers as we navigate the decline in COVID-19 testing demand and develop new products with the benefit of SDB's industry expertise and complementary offerings,” Meridian Chairman John McIlwraith said in the statement.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |